Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|June 26, 2018
Javara Launches Next Generation Integrated Clinical Trials Platform
Advertisement
Winston-Salem, North Carolina. Javara Inc., today announced the launch of its Integrated Research Organization (IRO) platform to drive innovative research partnerships, service, and technology offerings to healthcare systems, including
Accountable Care Organizations, Academic and Community-Based systems. Together, Javara and its healthcare partners will offer a more aligned, efficient, and effective solution to the challenges of patient inclusion in clinical trials, by creating an infrastructure where clinical research will become an integral part of the state-of-the-art healthcare delivery offered by Javara’s healthcare partners.
“Today, biopharmaceutical companies are developing truly innovative therapies for patients. Yet, patients, who simply cannot wait, continue to face incredible challenges in accessing clinical trials and frustration in the slow completion of clinical trials,” said Jeff Kasher, Ph.D, Pharmaceutical Development Executive and Javara Board Director. “By focusing on the healthcare ecosystem, Javara aims to make clinical research more efficient, relevant, and more accessible.”
Jennifer Byrne, co-founder and CEO of Javara is a long time clinical research leader with a proven track record. Under her leadership, Javara has assembled a top-flight talent team and a blue-chip Board of Directors (www.javararesearch.com), all deeply committed to advancing the relevance and efficiency of clinical research to the healthcare ecosystem. The Javara IRO platform will bring better outcomes for patient-centered care, better economic results and easier access to cutting edge therapies for healthcare systems, and a more valuable and reliable research delivery model to the biopharmaceutical sector. Ms. Byrne commented, “Strong market forces are driving the need for transformational and innovative partnerships for both healthcare organizations and drug and device developers, all while delivering a higher quality and higher touch clinical trial experience to patients. Historically, healthcare and drug development sectors have largely operated in silos. Javara’s mission is to build extraordinary bridges between healthcare and the research industry to effectively and efficiently accelerate drug development.”
Jennifer Byrne
CEO Javara
jbyrne@javararesearch.com
(336) 414-0814
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5